Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Corrigendum to 'Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients' [Gynecologic Oncology 152 (2019) 270-277].
Rodriguez-Freixinos V, Fariñas-Madrid L, Gil-Martin M, Barretina-Ginesta P, Romeo M, Villacampa G, Pardo B, Ahmed H, Recalde S, Piulats JM, Gomez-Plaza MC, Gil-Moreno A, Sala E, Martínez-Roman S, Ponce J, Melendez C, Carballas E, Dienstmann R, Oaknin A. Rodriguez-Freixinos V, et al. Among authors: recalde s. Gynecol Oncol. 2020 Jan;156(1):262. doi: 10.1016/j.ygyno.2019.10.020. Epub 2019 Nov 16. Gynecol Oncol. 2020. PMID: 31744639 No abstract available.
Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients.
Rodriguez-Freixinos V, Fariñas-Madrid L, Gil-Martin M, Barretina-Ginesta P, Romeo M, Villacampa G, Pardo B, Ahmed H, Recalde S, Piulats JM, Gómez-Plaza MC, Gil-Moreno A, Sala E, Martínez-Román S, Ponce J, Meléndez C, Carballas E, Dienstmann R, Oaknin A. Rodriguez-Freixinos V, et al. Among authors: recalde s. Gynecol Oncol. 2019 Feb;152(2):270-277. doi: 10.1016/j.ygyno.2018.11.036. Epub 2018 Dec 12. Gynecol Oncol. 2019. PMID: 30551885
Can we avoid axillary lymph node dissection in N2 breast cancer patients with chemo-sensitive tumours such as HER2 and TNBC?
Garcia-Tejedor A, Fernandez-Gonzalez S, Ortega R, Gil-Gil M, Perez-Montero H, Fernandez-Montolí E, Stradella A, Recalde S, Soler T, Petit A, Bajen MT, Benitez A, Guma A, Campos M, Pla MJ, Martinez E, Laplana M, Pernas S, Perez-Sildekova D, Catala I, Ponce J, Falo C. Garcia-Tejedor A, et al. Among authors: recalde s. Breast Cancer Res Treat. 2021 Feb;185(3):657-666. doi: 10.1007/s10549-020-05970-2. Epub 2020 Oct 17. Breast Cancer Res Treat. 2021. PMID: 33068198
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.
Bardia A, Tolaney SM, Punie K, Loirat D, Oliveira M, Kalinsky K, Zelnak A, Aftimos P, Dalenc F, Sardesai S, Hamilton E, Sharma P, Recalde S, Gil EC, Traina T, O'Shaughnessy J, Cortes J, Tsai M, Vahdat L, Diéras V, Carey LA, Rugo HS, Goldenberg DM, Hong Q, Olivo M, Itri LM, Hurvitz SA. Bardia A, et al. Among authors: recalde s. Ann Oncol. 2021 Sep;32(9):1148-1156. doi: 10.1016/j.annonc.2021.06.002. Epub 2021 Jun 8. Ann Oncol. 2021. PMID: 34116144 Free article. Clinical Trial.
Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center.
Sirvén MB, Fernández-Ortega A, Stradella A, Morilla I, Falo C, Vázquez S, Castany R, Villanueva R, Recalde S, Pérez VN, Gil-Gil M, Pernas S. Sirvén MB, et al. Among authors: recalde s. BMC Pharmacol Toxicol. 2019 Nov 21;20(1):68. doi: 10.1186/s40360-019-0367-x. BMC Pharmacol Toxicol. 2019. PMID: 31753013 Free PMC article.
Validation and comparison of Breast Graded Prognostic Assessment scores in patients with breast cancer and brain metastases.
Fabregat-Franco C, Stradella A, Navarro V, Linares J, Galdeano M, Recalde S, Velasco R, Simo M, Fernadez A, Venthecourt AC, Falo C, Vazquez S, Bergamino M, Villanueva R, Pernas S, Gil-Gil MJ. Fabregat-Franco C, et al. Among authors: recalde s. Clin Transl Oncol. 2021 Sep;23(9):1761-1768. doi: 10.1007/s12094-021-02577-x. Epub 2021 Mar 11. Clin Transl Oncol. 2021. PMID: 33704689
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortés J, O'Shaughnessy J, Diéras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS; ASCENT Clinical Trial Investigators. Bardia A, et al. N Engl J Med. 2021 Apr 22;384(16):1529-1541. doi: 10.1056/NEJMoa2028485. N Engl J Med. 2021. PMID: 33882206 Clinical Trial.
Genomic characterization and tumor evolution in paired samples of metaplastic breast carcinoma.
Stradella A, Gargallo P, Cejuela M, Petit A, Bosch-Schips J, Carbonell P, Recalde S, Vethencourt A, Fernandez-Ortega A, Falo C, Gil-Gil M, Vázquez S, Obadia V, Villanueva-Vázquez R, Soler-Monsó T, Calabria I, Pernas S. Stradella A, et al. Among authors: recalde s. Mod Pathol. 2022 Aug;35(8):1066-1074. doi: 10.1038/s41379-022-01017-7. Epub 2022 Feb 17. Mod Pathol. 2022. PMID: 35177782 Free article.
Breast Cancer Patient's Outcomes after Neoadjuvant Chemotherapy and Surgery at 5 and 10 Years for Stage II-III Disease.
Falo C, Azcarate J, Fernandez-Gonzalez S, Perez X, Petit A, Perez H, Vethencourt A, Vazquez S, Laplana M, Ales M, Stradella A, Fullana B, Pla MJ, Gumà A, Ortega R, Varela M, Pérez D, Ponton JL, Cobo S, Benitez A, Campos M, Fernández A, Villanueva R, Obadia V, Recalde S, Soler-Monsó T, Lopez-Ojeda A, Martinez E, Ponce J, Pernas S, Gil-Gil M, Garcia-Tejedor A. Falo C, et al. Among authors: recalde s. Cancers (Basel). 2024 Jun 30;16(13):2421. doi: 10.3390/cancers16132421. Cancers (Basel). 2024. PMID: 39001483 Free PMC article.
Assessing the Prognostic Value of Cytoplasmic and Stromal Caveolin-1 in Early Triple-Negative Breast Cancer Undergoing Neoadjuvant Chemotherapy.
Teruel I, Castellà E, Recalde S, Viñas G, Petit A, Trigueros M, Martínez-Balibrea E, Felip E, Bergamino M, Bernat-Peguera A, Cirauqui B, Quiroga V, Ferrando-Díez A, Pous A, López A, Boronat L, Soler G, Recuero J, Romeo M, Guillén P, Mesía R, Ballana E, Martínez-Cardús A, Margelí M. Teruel I, et al. Among authors: recalde s. Int J Mol Sci. 2024 Nov 14;25(22):12241. doi: 10.3390/ijms252212241. Int J Mol Sci. 2024. PMID: 39596307 Free PMC article.
65 results